The Scientist profiles Mireille Gingras' company, HUYA Bioscience International, which focuses on finding early-stage drug compounds from China. HUYA, the article says, has a codevelopment model in which it licenses the compounds for development for Western markets and the Chinese company retains the rights to the Chinese market.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.